Related Experiment Videos
Hypertrophic osteoarthropathy effectively treated with zoledronic acid
Melissa M King1, Douglas A Nelson
1Department of Hematology/Oncology, Wilford Hall Medical Center, Lackland Air Force Base, San Antonio, TX 78236, USA. melissa.king@lackland.af.mil
Clinical Lung Cancer
|July 16, 2008
Summary
Hypertrophic osteoarthropathy (HOA), a painful condition linked to lung cancer, saw complete symptom resolution after a single zoledronic acid dose. This suggests bisphosphonates may effectively treat HOA pain and swelling.
Area of Science:
- Oncology
- Rheumatology
- Pharmacology
Background:
- Hypertrophic osteoarthropathy (HOA) is a clinical syndrome often associated with bronchogenic carcinoma.
- HOA presents with digital clubbing, arthralgias, and tissue swelling, causing disabling pain resistant to standard analgesics.
Observation:
- A patient with HOA of the lower extremities and wrists, secondary to bronchogenic carcinoma, was treated.
- Symptoms of pain and swelling were completely resolved following a single 4 mg zoledronic acid administration.
Findings:
- Zoledronic acid, a bisphosphonate, demonstrated significant efficacy in alleviating HOA symptoms.
- This case highlights a potential therapeutic role for bisphosphonates in managing HOA.
Implications:
- Bisphosphonates may offer a novel treatment avenue for patients suffering from HOA, particularly when linked to malignancy.
- Further research into the mechanism of bisphosphonates in HOA pathogenesis is warranted.
Related Concept Videos
01:31Osteoclasts in Bone Remodeling
Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during bone...
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...